C12N 2750/14023
Virus like particles [vlp]
Official title: Virus like particles [VLP]
C12N2750/14023 (Virus like particles [vlp]) appears on 9 US grants and 14 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 14
- Assignees
- 10
- Inventors
- 28
- Latest grant
- 17 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 1 | 3 |
| 2016 | 0 | 0 |
| 2017 | 2 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 1 |
| 2020 | 0 | 1 |
| 2021 | 0 | 2 |
| 2022 | 3 | 3 |
| 2023 | 1 | 1 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and kits for quantifying the removal of mock virus particles from a purified solution17 Feb 2026US 12,553,894 B2Cygnus Technologies, L.L.C.
- Methods and kits for quantifying the removal of mock virus particles from a purified solution12 Sep 2023US 11,754,565 B2MockV Solutions, Inc.
- Compositions and methods for the targeting of rhodopsin27 Dec 2022US 11,535,835 B1Scribe Therapeutics Inc.
- Coronavirus immunogenic compositions and uses thereof12 Jul 2022US 11,382,968 B2Altimmune Inc.
- Murine parvovirus and uses thereof17 May 2022US 11,332,720 B2Centenary Institute of Cancer Medicine and Cell Biology
- Methods and kits for quantifying the removal of mock virus particles from a purified solution14 Mar 2024US 2024/0085419 A1MockV Solutions, Inc.
- Compositions and methods for the targeting of rhodopsin2 Feb 2023US 2023/0033866 A1Scribe Therapeutics Inc.
- Regeneration of retinal ganglion cells3 Nov 2022US 2022/0347320 A1
- Oligonucleotides and methods for the treatment of age-related macular degeneration23 Jun 2022US 2022/0195428 A1The Genera Hospital Corporation
- Coronavirus immunogenic compositions and uses thereof10 Mar 2022US 2022/0072121 A1Altimmune Inc.
Most cited
By later US patents
- Compositions and methods for the targeting of rhodopsin5US 11,535,835 B1Scribe Therapeutics Inc. · 2022
- Methods for evaluating viral clearance from a biopharmaceutical solution employing mock viral particles4US 9,632,087 B2MockV Solutions, Inc. · 2017
- Coronavirus immunogenic compositions and uses thereof3US 11,382,968 B2Altimmune Inc. · 2022
- Methods for evaluating viral clearance from a process solution employing mock viral particles1US 10,309,963 B2MockV Solutions, Inc. · 2019
- Methods and kits for quantifying the removal of mock virus particles from a purified solution1US 11,754,565 B2MockV Solutions, Inc. · 2023